Research and Markets: Renal Cancer Drug Pipeline Update 2015 - 182 Companies Plus Partners Developing 211 Drugs
January 26 2015 - 5:07AM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/ssmzdq/renal_cancer_drug)
has announced the addition of the "Renal Cancer Drug Pipeline
Update 2015" report to their offering.
The high existing unmet need in the treatment of renal cancer is
reflected by the poor prognosis of patients with advanced stage
disease, five- year survival rates with existing cytokine therapy
being less than 20% (RCC) in this patient cohort.The identification
of biomarkers is set to revolutionize patient staging and prognosis
by individualizing patient treatments and creating novel drug
targets.
There are today 182 companies plus partners developing 211 drugs
targeting renal cancer in development. In addition, there are 3
suspended drugs and the accumulated number of ceased drugs over the
last years amount to another 95 drugs.
Renal Cancer Drug Pipeline Update lists all drugs and gives you
a progress analysis on each one of them. Identified drugs are
linked to 210 different targets. All included targets have been
cross-referenced for the presence of mutations associated with
human cancer.
To date 203 out of the 206 studied drug targets so far have been
recorded with somatic mutations. The software application lets you
narrow in on these mutations and links out to the mutational
analysis for each of the drug targets for detailed information. All
drugs targets are further categorized on in the software
application by 53 classifications of molecular function and with
pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed 25
- Registered 1
- Pre-registration 1
- Phase III 12
- Phase II 79
- Phase I 67
- Preclinical 26
- Suspended 3
- Ceased 95
For more information visit
http://www.researchandmarkets.com/research/ssmzdq/renal_cancer_drug
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Oncology